No Data
Ironwood Pharmaceuticals' (NASDAQ:IRWD) Challenges Continue With Q1 Misses
US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price target from $18 to $14.
Ironwood Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 102.17% Craig-Hallum $18 → $14 Maintains Buy 03/01/2024 102.17% Wells Fargo $20 → $14 Maintains
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Ironwood Pharmaceuticals, Inc. IRWD reported an adjusted loss of 2 cents per share for first-quarter 2024 in contrast to the Zacks Consensus Estimate of earnings of 18 cents per share.
Jimmy1819 : have you been investing professionally or as a hobby?